The invention provides compounds of formula (I):
wherein R
1
and R
2
are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
Hydantoin compounds and pharmaceutical compositions thereof
申请人:AstraZeneca AB
公开号:US08183251B2
公开(公告)日:2012-05-22
The invention provides compounds of formula (I):
wherein R1 and R2 are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
[EN] HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOINE UTILISÉS COMME INHIBITEURS DE MMP
申请人:ASTRAZENECA AB
公开号:WO2008065393A1
公开(公告)日:2008-06-05
[EN] The invention provides compounds of formula (I): wherein R1 and R2are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors. [FR] L'invention porte sur des composés représentés par la formule (I): dans laquelle R1 et R2 sont tels que définis dans la description; sur des procédés pour leur préparation; sur des compositions pharmaceutiques les contenant; un procédé de fabrication des compositions pharmaceutiques; et sur leur utilisation en thérapie. Les composés sont utiles comme inhibiteurs de MMP.